News

The Koehler Lab at MIT acknowledges Pelago Bioscience’s patent and use of CETSA® process

Pelago Bioscience celebrates that the Koehler Lab at the Massachusetts Institution of Technology found CETSA® to be a valuable method for quantifying drug Target Engagement in the lab’s experiments described in Richters et al., “Modulating Androgen Receptor-Driven Transcription in Prostate Cancer with Selective CDK9 Inhibitors,” Cell Chem. Biol., 28(2):134-147, 2021.


Michael Dabrowski, CEO of Pelago Bioscience comments on the publication: “We are thrilled that investigators in the Koehler Lab at MIT found the CETSA® technology a valuable method for quantifying drug Target Engagement. I encourage other investigators and those involved in the drug discovery community to engage with Pelago to explore how we can enhance their discovery efforts with the use of our CETSA® technology platform and derived services.”

Stockholm, 16 September 2024